Seres Therapeutics MCRB Estimates

NASDAQ MCRB
$5.09 -0.19 (-3.60%)
As of: Sep 10, 2026 · 12:13 PM EDT
Analyst Estimates

Seres Therapeutics, Inc. Revenue Estimates

Periods 26
Next Period Q4 25
Consensus 0.00

Analysts expect Seres Therapeutics, Inc. to report revenue of 0.00 for Q4 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 736,000.00, a 334.5% beat against the 169,393.96 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 0.000.000.000.00351,000.00-358,000.00736,000.00-------
High Estimate 35.92 M0.0010.29 M0.008.44 M0.000.00185,802.146.96 M6.72 M-912,694.22-2.52 M1.76 M2.47 M-633,030.82
Low Estimate 30.32 M0.009.18 M0.007.59 M0.000.00152,985.786.43 M5.53 M-1.09 M-2.98 M1.44 M2.20 M-742,329.32
Consensus Estimate 33.12 M0.009.73 M0.008.01 M0.000.00169,393.966.70 M6.12 M-999,244.81-2.75 M1.60 M2.33 M-687,680.07
Analyst Estimates

Seres Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus -1.05

Analysts expect Seres Therapeutics, Inc. to report earnings per share of -1.05 for Q3 26, against a range of -1.12 to -0.98. The most recent reported quarter, Q2 26, came in at 0.47, a 122.4% beat against the -2.10 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 11.60-1.803.75-2.270.94-1.78-2.080.47--------
High Estimate -1.48-3.580.11-2.420.47-2.03-1.82-1.89-0.98-0.93-1.080.11-1.07-2.66-0.760.25
Low Estimate -1.70-4.020.09-2.720.41-2.37-2.14-2.31-1.12-1.03-1.240.09-1.17-3.12-0.880.23
Consensus Estimate -1.59-3.800.10-2.570.44-2.20-1.98-2.10-1.05-0.98-1.160.10-1.12-2.89-0.820.24